机器人胃切除术是超重胃癌患者的可靠选择:倾向性评分匹配研究
本研究回顾性分析2016年8月至2019年12月期间接受微创根治性胃切除术的482例BMI≥25 kg/m2的胃腺癌患者,其中机器人胃切除术(RG)组109例,腹腔镜胃切除术(LG)组321例,经1:1倾向性评分匹配后每组109例。结果显示RG组与LG组在术中估计出血量、术后并发症、术后恢复、淋巴结清扫总数、教科书结局以及3年总生存率和无病生存率方面均相似。结论认为,在BMI≥25 kg/m2的选定患者队列中,RG提供了与LG相当的淋巴结清扫、术后恢复和肿瘤学结局。
要点
- 在BMI≥25 kg/m2的胃腺癌患者中,机器人胃切除术与腹腔镜胃切除术的3年总生存率(80.7% vs. 81.7%)和无病生存率(78% vs. 76.1%)相当。
- 机器人胃切除术的术后并发症发生率为13.8%,腹腔镜胃切除术为18.3%,OR 0.71(95%CI 0.342至1.473)。
- 机器人胃切除术在淋巴结清扫总数和教科书结局方面与腹腔镜胃切除术相似。
核心结论
- 在BMI≥25 kg/m2的选定患者队列中,机器人胃切除术提供了与腹腔镜胃切除术相当的淋巴结清扫、术后恢复和肿瘤学结局。
研究设计与样本
- 回顾性分析2016年8月至2019年12月期间接受微创根治性胃切除术的482例BMI≥25 kg/m2的胃腺癌患者,其中机器人胃切除术组109例,腹腔镜胃切除术组321例,并进行1:1倾向性评分匹配。
主要发现
- 倾向性评分匹配后每组109例,基线特征均衡;机器人胃切除术组与腹腔镜胃切除术组的术中估计出血量中位数(IQR)分别为30(20-50)mL和35(30-59)mL,中位差值(95%CI)为-5(-10至0)mL。
- 机器人胃切除术组与腹腔镜胃切除术组的术后并发症发生率分别为13.8%和18.3%,OR(95%CI)为0.71(0.342至1.473)。
- 机器人胃切除术组与腹腔镜胃切除术组的淋巴结清扫总数分别为34.25±13.43枚和35.44±14.12枚,均值差值(95%CI)为-1.19(-4.871至2.485)枚。
- 机器人胃切除术组与腹腔镜胃切除术组的教科书结局分别为81.7%和76.1%,OR(95%CI)为1.39(0.724至2.684)。
- 在病理分期II-III期接受化疗的患者中,机器人胃切除术组与腹腔镜胃切除术组的辅助化疗开始时间中位数(IQR)分别为28(25.5-32.5)天和32(27-38.5)天,中位差值(95%CI)为-3(-6至0)天。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The role of minimally invasive surgery using robotics versus laparoscopy in resectable gastric cancer patients with a high body mass index (BMI) remains controversial. METHODS: A total of 482 gastric adenocarcinoma patients with BMI ≥ 25 kg/m2 who underwent minimally invasive radical gastrectomy between August 2016 and December 2019 were retrospectively analyzed, including 109 cases in the robotic gastrectomy (RG) group and 321 cases in the laparoscopic gastrectomy (LG) group. Propensity score matching (PSM) with a 1:1 ratio was performed, and the perioperative outcomes, lymph node dissection, and 3-year overall survival (OS) and disease-free survival (DFS) rates were compared. RESULTS: After PSM, 109 patients were included in each of the RG and LG groups, with balanced baseline characteristics. Compared with the LG group, the RG group had similar intraoperative estimated blood loss [median (IQR) 30 (20-50) vs. 35 (30-59) mL, median difference (95%CI) - 5 (- 10 to 0)], postoperative complications [13.8% vs. 18.3%, OR (95%CI) 0.71 (0.342 to 1.473)], postoperative recovery, total harvested lymph nodes [(34.25 ± 13.43 vs. 35.44 ± 14.12, mean difference (95%CI) - 1.19 (- 4.871 to 2.485)] and textbook outcomes [(81.7% vs. 76.1%, OR (95%CI) 1.39 (0.724 to 2.684)]. Among pathological stage II-III patients receiving chemotherapy, the initiation of adjuvant chemotherapy in the RG group was similar to that in the LG group [median (IQR): 28 (25.5-32.5) vs. 32 (27-38.5) days, median difference (95%CI) - 3 (- 6 to 0)]. The 3-year OS (RG vs. LG: 80.7% vs. 81.7%, HR = 1.048, 95%CI 0.591 to 1.857) and DFS (78% vs. 76.1%, HR = 0.996, 95%CI 0.584 to 1.698) were comparable between the two groups. CONCLUSION: RG conferred comparable lymph node dissection, postoperative recovery, and oncologic outcomes in a selected cohort of patients with BMI ≥ 25 kg/m2.
引用
- Wei LH, Zheng HL, Xue Z, et al. Robotic gastrectomy was reliable option for overweight patients with gastric cancer: a propensity score matching study. Surg Endosc. 2024. PMID: 38627257. doi:10.1007/s00464-024-10845-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。